MTB对阿米卡星和卡那霉素耐药相关rrs与eis基因突变的研究

Study on mutations of ms and eis genes in Mycobacterium tuberculosis resistant to amikacin and kanamycin

本研究搜集了吉林省全部9个地级市结核病医疗机构2014-2017年内1357株结核分枝杆菌分离株。采用比例法进行Am和Km的药物敏感性试验，并对rrs和eis缸基因进行PCR和测序分析。发现28株同时耐Km和Am，单耐Km者有2株；其中26株MTB的rrs基因均发生突变，基因突变率为92．86％；6株菌存在g妇基因突变，突变率为21．43％。60株对照株未发现基因突变。吉林省MTB对Am和Kin存在较高的交叉耐药现象；rrs基因的突变可以作为两者交叉耐药的分子标志，为建立耐Am和（或）Km结核病快速检测技术提供分子基础。

1357 Mycobacterium tuberculosis （MTB） isolates were collected from tuberculosis medical institu- tions in nine prefectures of Jilin Province from 2014 to 2017. Amikacin （Am） and kanamycin （Km） susceptibility tests were performed by proportional method, and rrs and eis genes were analyzed by PCR and sequencing. Twenty-eight strains were resistant to both Km and Am, and 2 strains were resistant to Km alone, rrs gene mutation occurred in 26 strains resistant to Am and Kin, and the mutation rate was 92.86%. eis gene mutation occurred in 6 strains, and the mutation rate was 21. 430%. No mutation was found in 60 control strains. MTB had high cross resistance to Am and Km in Jilin Province. The mutation of rrs gene can be used as a molecular marker of cross resistance, which can provide molecular basis for the establishment of rapid detection technology for tuberculosis resistant to Am and/or Km.